28.5 C
Munich
Friday, June 28, 2024
type here...
- Advertisement -
- Advertisement -spot_img

TAG

LECANEMAB

Marketing & Advertising

Eisai recordsdata advertising authorization software for lecanemab in Europe and Japan

Spam -
Following the US approval of the drug on January 6 beneath the business title Leqembi, Tokyo-headquartered Eisai (which takes the lead on the...
Marketing & Advertising

Eisai information advertising and marketing authorization utility for lecanemab in Europe and Japan

Spam -
Following the US approval on January 6 beneath the business title Leqembi, Tokyo-headquartered Eisai (which takes the lead on the collaboration with Biogen...
Marketing & Advertising

BioArctic’s associate Eisai submits advertising authorization utility for lecanemab as remedy for early Alzheimer’s illness in Japan

Spam -
STOCKHOLM, Jan. 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) associate Eisai introduced immediately that Eisai has submitted a advertising...
Marketing & Advertising

BioArctic’s accomplice Eisai submits advertising and marketing authorization software for lecanemab as therapy for early Alzheimer’s illness in Japan

Spam -
STOCKHOLM, Jan. 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) accomplice Eisai introduced at present that Eisai has submitted a...
Marketing & Advertising

EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN JAPAN

Spam -
TOKYO and CAMBRIDGE, Mass., Jan. 15, 2023 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB,...

Latest news

- Advertisement -spot_img

© Munich, LLC. All rights reserved. Pulses Pro® is a registered U.S. trademark of tagDiv, LLC.

- Advertisement -

About Us

Popular Category

Editor Picks